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TRENDS IN INPATIENT COSTS FOR ACUTE 
PANCREATITIS IN THE UNITED STATES
Bell CF, Stephens JM, Botteman MF, Pashos CL, Ewing M
Abt Associates Clinical Trials, Bethesda, MD, USA
Although the care of patients with pancreatitis-related
complications is estimated to be much more resource-
intensive than that provided to other critically-ill patients,
information on the cost of acute pancreatitis is limited.
OBJECTIVES: To examine trends in the incidence and
cost of acute pancreatitis-related hospitalizations in the
United States, and to ascertain patient disposition at dis-
charge to evaluate the extent to which costs may extend
beyond the initial hospitalization. METHODS: Data
were obtained from the 1995–1997 Health care Cost and
Utilization Project database. ICD-9-CM code 577.0 was
used to identify hospitalizations with a primary or sec-
ondary diagnosis of acute pancreatitis. Patient demo-
graphics, length of stay (LOS), total charges (in constant
1995 dollars), and discharge status were assessed. RE-
SULTS: Between 1995 and 1997, the number of acute
pancreatitis-related hospitalizations increased by 9.1%
from 241,178 to 263,136. During that period, the aver-
age LOS decreased by 9.5% from 8.4 days to 7.6 days
and the mean hospital charges decreased by 4.9% from
$19,222 to $18,280. Using LOS 15 days as a proxy for
severity, severe acute pancreatitis-related hospital dis-
charges decreased from 30,444 in 1995 to 27,839 in
1997. During that period, the average LOS remained
constant (28.9–28.4 days) and the mean charges in-
creased from $77,572 to $82,043. Nationwide, the pro-
jected pancreatitis-related inpatient charges have in-
creased from $4.6 to $4.8 billion. Despite representing
12% of admissions, severe acute pancreatitis-related
charges represented 49% of all acute pancreatitis-related
inpatient charges. 38–41% of patients were discharged to
another facility, suggesting that these cost estimates are
conservative. CONCLUSIONS: Acute pancreatitis is a
major financial burden on health care systems due to
high inpatient costs and frequent need for medical care
that extends beyond the hospital stay. Despite a reduc-
tion in charge per case, total inpatient charges of pancre-
atitis have increased to rising incidence.
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It is necessary to understand the direct and indirect costs
of HIV infection in untreated workers in order to esti-
mate the value of aggressive antiretroviral therapies from
an employer’s perspective. Currently the cost of HIV/
AIDS from an employer’s perspective is not well under-
stood. OBJECTIVES: To estimate lifetime costs of HIV
infection in untreated employees from an employer’s per-
spective. METHODS: A simulation model was developed
to predict costs of HIV infection in untreated employees
from an employer’s perspective over a ten-year time
frame. This model utilized age, CD4 cell counts, and
plasma HIV-1 RNA level as major predictors of disease
progression and expected patient survival to estimate life-
time costs. Major direct cost components were health in-
surance premium, life insurance premium, short-term dis-
ability benefits, long-term disability benefits, and hiring/
training expenses. The indirect cost included productivity
loss at work. RESULTS: For a hypothetical 35-year old
HIV-positive employee with CD4 cell counts at 380
cells/mm3 and HIV-1 RNA at 22,000 copies/ml, the
model estimated that the total direct and indirect costs of
HIV infection was $165,873 from the employer’s per-
spective over a 10-year period. This included $66,659 for
health insurance, $12,788 for life insurance costs, $8,580
for short-term and long-term disability benefits, $25,894
for hiring and training expenses and $51,952 due to pro-
ductivity loss. Sensitivity analyses suggested that changes
in employee age, CD4 cell count, HIV-1 RNA viral
load, and CD4 cell decline rate were important param-
eters that significantly impact the costs of untreated HIV
workers to employers. CONCLUSION: Without effec-
tive antiretroviral therapy, HIV infection could result in
significant direct and indirect costs to employers. There-
fore, the cost-effectiveness of treatment with advanced
antiretroviral regimen should be considered for HIV in-
fected workers.
PID5
MOXIFLOXACIN VS AMOXICILLIN/
CLAVULANATE IN THE TREATMENT OF ACUTE 
MAXILLARY SINUSITIS (AMS):
EFFICACY, SAFETY AND PATIENT-REPORTED
OUTCOMES IN PRIMARY CARE
Rakkar S
Plano Medical Center, Plano, TX, USA
OBJECTIVE: This study was designed to reflect real-
world experience in the treatment of patients with AMS.
Efficacy, safety, and patient-reported outcomes variables
were compared between moxifloxacin (MXF) and amox-
icillin/clavulanate (AC) for the management of AMS in a
primary care setting. METHODS: In this prospective,
multicenter, non-blinded phase IIIb trial, 475 adult pa-
tients with symptoms of AMS were randomized to re-
ceive a 10-day oral regimen of either MXF (400mg once-
daily) or AC (875mg twice-daily). Clinical success at the
test-of-cure (TOC) visit (post-therapy days 14–21) was
the primary efficacy measure. Secondary outcomes in-
cluded rate of clinical relapse at follow-up (post-therapy
days 26–46) and exploratory evaluation of patient-
reported outcomes variables. Safety data was also tabu-
lated from intent-to-treat (ITT) patients. RESULTS: Of
